MannKind | MNKD - Actif À Court Terme





Actif À Court Terme Changement Date
Adma Biologics USD 466.51M 63.86M 2025-12
BioCryst Pharmaceuticals USD 404.35M 48.66M 2025-12
Eli Lilly USD 55.63B 6.44B 2025-12
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
Insmed USD 1.79B 137.6M 2025-12
Karyopharm Therapeutics USD 89.75M 8.12M 2025-09
MacroGenics USD 219.94M 12.15M 2025-12
MannKind USD 291.58M 67.26M 2025-12
Merck USD 47.56B 10.49B 2025-09
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Novavax USD 978.28M 3.69M 2025-12
Novo Nordisk DKK 25.71B 148.69B 2025-06
Pfizer USD 46.92B 3.22B 2025-09
Sanofi EUR 30.95B 3.09B 2025-12
Xencor USD 599.82M 81.38M 2025-12